Browsing NTNU Open by Author "Giliberto, Mariaserena"
Now showing items 1-4 of 4
-
Flow analysis of RANK expression on myeloid cells and identification of bone marrow cells expressing IL-32 in multiple myeloma patients
Giliberto, Mariaserena (Master thesis, 2016)Multiple myeloma is the second most common hematological cancer worldwide, characterized by an increased expansion of malignant plasma cells in the bone marrow, organ dysfunction, immunodeficiency and bone erosion. Nearly ... -
Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss
Zahoor, Muhammad; Westhrin, Marita; Aass, Kristin Roseth; Moen, Siv Helen; Misund, Kristine; Psonka-Antonczyk, Katarzyna Maria; Giliberto, Mariaserena; Buene, Glenn; Sundan, Anders; Waage, Anders; Sponaas, Anne-Marit; Standal, Therese (Journal article; Peer reviewed, 2017)Multiple myeloma (MM) is a hematologic cancer characterized by expansion of malignant plasma cells in the bone marrow. Most patients develop an osteolytic bone disease, largely caused by increased osteoclastogenesis. The ... -
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies
Melvold, Katrine; Giliberto, Mariaserena; Karlsen, Linda; Ayuda-Duran, Maria del Pilar; Hanes, Robert; Holien, Toril; Enserink, Jorrit; Brown, Jennifer R.; Tjønnfjord, Geir Erland; Tasken, Kjetil; Skånland, Sigrid Strand (Peer reviewed; Journal article, 2021)Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. ... -
Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines
Giliberto, Mariaserena; Miranda Santana, Leonardo; Holien, Toril; Misund, Kristine; Nakken, Sigve; Vodak, Daniel; Hovig, Eivind; Meza, Leonardo Zepeda; Coward, Eivind; Waage, Anders; Tasken, Kjetil; Skånland, Sigrid S (Peer reviewed; Journal article, 2022)Introduction: Multiple myeloma (MM) is a heterogeneous disease where cancer-driver mutations and aberrant signaling may lead to disease progression and drug resistance. Drug responses vary greatly, and there is an unmet ...